$143.75 Million

Rhythm Pharmaceuticals

Follow-on Offering

Lead Left Bookrunner, September 2022

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. (the “Company”) is a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor pathway (MC4R) diseases. The Company’s precision medicine, IMCIVREE (or setmelanotide), is approved by the U.S. Food and Drug Administration for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). The Company is also advancing a broad clinical development program for setmelanotide in other rare MC4R pathway diseases and is leveraging the Rhythm Engine and the largest known obesity DNA database to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies.